HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (86) Citing Articles via Google Scholar Google Scholar Articles by Gompertz, S. Articles by Stockley, R.A. Search for Related Content PubMed PubMed Citation Articles by Gompertz, S. Articles by Stockley, R.A.

Changes in bronchial inflammation during acute exacerbations of chronic bronchitis

Dept of Respiratory Medicine, Queen Elizabeth Hospital, Birmingham, UK

CORRESPONDENCE: S. Gompertz, Dept of Respiratory Medicine, First Floor, Nuffield House Q. E. Hospital, Edgbaston, Birmingham, B15 2TH, UK

Keywords: bronchitis, chronic bronchitis, exacerbations, inflammation

Received: December 31, 1999
Accepted January 8, 2001

This work was supported by an unrestricted educational grant from GlaxoSmith-Kline.

	Abstract

TOP Abstract Methods Results Discussion Acknowledgements References

 
There are little data describing noncellular changes in bronchial inflammation during exacerbations of chronic bronchitis. The relationship between sputum colour and airway inflammation at presentation has been assessed during an exacerbation in patients with chronic bronchitis and a primary care diagnosis of chronic obstructive pulmonary disease.

Sputum myeloperoxidase, neutrophil elastase, leukotriene B₄ (LTB₄), interleukin-8 (IL-8), sol:serum albumin ratio and serum C-reactive protein were measured in patients presenting with an exacerbation and mucoid (n=27) or purulent sputum (n=42).

Mucoid exacerbations were associated with little bronchial or systemic inflammation at presentation, and sputum bacteriology was similar to that obtained in the stable state. Purulent exacerbations were associated with marked bronchial and systemic inflammation (p<0.025 for all features) and positive sputum cultures (90%). Resolution was related to a significant reduction in LTB₄ (p<0.01), but no change in IL-8, suggesting that LTB₄ may be more important in neutrophil recruitment in these mild, purulent exacerbations. In the stable state, IL-8 remained higher in patients who had experienced a purulent exacerbation (2p<0.02).

The presented results indicate that exacerbations of chronic bronchitis, defined by sputum colour, differ in the degree of bronchial and systemic inflammation. Purulent exacerbations are related to bacterial infection, and are associated with increased neutrophilic inflammation and increased leukotriene B₄ concentrations.

Exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD) are related to increased morbidity and mortality, and are usually defined on clinical grounds as a worsening of respiratory symptoms 1, 2. The nature of these exacerbations is loosely defined and some may reflect an increase in airflow obstruction, whilst others (which may be related to bacterial infection) are associated with an influx of neutrophils 3–5, sputum purulence and increased neutrophil elastase activity 6. The loose definition and heterogeneous aetiology of exacerbations may explain studies which show that the use of steroids 7, antibiotics 2 and placebo 2 are all associated with resolution of symptoms. In addition, the characterization of exacerbations in studies of patients with lung disease is often relatively superficial and depends largely on clinical symptoms and simple physiological measurements. For instance, recent data have shown that a significant proportion of patients (30%), classified as having COPD by their primary care physician (on clinical grounds alone), have radiological evidence of bronchiectasis detectable by high-resolution computed tomography (HRCT) scanning 8. This heterogeneity adds further difficulties when interpreting published literature. Data relating to bronchial inflammation during exacerbations of chronic bronchitis and/or COPD are confined largely to descriptions of inflammatory cell numbers during an exacerbation, and in the stable clinical state 3–5, 9. The number of patients in these studies is small (generally<25), and has usually involved the assessment of different patients during the exacerbation and in the stable state 3–6, 9.

The purpose of the present study, therefore, was to assess the biochemical nature and resolution of airway inflammation in a large group of patients with smoking-related chronic bronchitis and a primary care diagnosis of COPD, who presented with an acute exacerbation. In particular, the aim was to determine whether the macroscopic nature of the secretions reflected the degree of airway inflammation, and whether this influenced the biochemical resolution of the exacerbation.

	Methods

TOP Abstract Methods Results Discussion Acknowledgements References

 
Subjects
The present study identified patients aged 40–80 yrs who presented to their primary care physician with an acute exacerbation of chronic bronchitis (daily sputum production for at least 3 months of 2 consecutive years), and in whom a diagnosis of COPD had been made on clinical grounds alone. An exacerbation was identified as a combination of worsening respiratory symptoms (including breathlessness, sputum volume, colour or viscosity, cough, wheeze or chest pain), with or without systemic symptoms (malaise; fever; rigors), which caused the patient to seek medical advice. Those who had received recent antibiotic therapy (previous 4 weeks) or where oral corticosteroid therapy or hospital admission were thought to be mandatory were excluded from the study.

The study was approved by the South Birmingham Health Authority Ethics Committee and all subjects provided written informed consent.

Sputum classification
Patients were seen by a respiratory nurse on the day of presentation (day 1), and a fresh spontaneous sputum sample was obtained. An experienced microbiology technician allocated the sample a number by reference to a standard colour chart (BronkoTest, Heredilab Inc., Salt Lake City, UT, USA) according to its predominant macroscopic appearance. Values of 0–2 (colourless-white) were classified as mucoid, and 3–8 (ranging from pale yellow to dark green) as increasingly purulent sputum.

Quantitative sputum culture was performed on an aliquot of the initial sample as described previously 10. The remaining sputum was centrifuged at 50,000xg (4°C) for 90 mins and the sputum sol phase was harvested and stored at –70°C until analysed. Ten millilitres of blood was also obtained, allowed to clot, centrifuged at 3,000 revolutions per minute (rpm) for 10 mins and the serum was stored at –70°C until required.

Treatment protocol
All subjects were treated and followed as outpatients. Patients with mucoid exacerbations had any regular inhaled corticosteroid prescribed prior to study entry stopped; although all other therapies, including beta-2 agonists and anticholinergic agents, were continued. These subjects then received either fluticasone propionate (1,000 µg per day by metered dose inhaler) or matching placebo for 14 days, in order to determine whether inhaled steroids alter lung inflammation. This dose was chosen as it has been shown to have an anti-inflammatory effect on lung secretions 11, and to reduce the severity of exacerbations in patients with COPD 12.

Individuals with macroscopically purulent sputum (colour numbers 3) received either 10 days of continuous therapy with oral cefuroxime axetil (500 mg twice daily) or 5 days of therapy followed by 5 days of placebo tablets. The antibiotic was chosen because of its known activity against the respiratory pathogens most commonly identified in exacerbations of COPD, namely Streptococcus pneumoniae, nontypeable Haemophilus influenzae and Moraxella catarrhalis 13.

Subsequent visits
Patients were reviewed by the study team on the fifth day of treatment (day 5), at the end of the treatment period (day 10 for purulent and day 14 for mucoid exacerbations), and 28 and 56 days after presentation, when in the stable clinical state. Further blood and sputum samples (over 4 h from rising) were obtained on the day of each visit and whenever possible (providing no further exacerbation was present), processed and stored as stated previously. On day 56 (in the stable clinical state), quantitative sputum bacteriology was repeated and dynamic lung volumes were measured using a wedge bellows spirometer (Vitalograph, Buckinghamshire, UK). Short-acting bronchodilators were omitted for 6 h prior to spirometry and long-acting bronchodilators for 12 h. The best of three satisfactory traces agreeing within 50 mL for forced expiratory volume in one second (FEV₁) and 150 mL for vital capacity (VC) were accepted for analysis. The measurements were repeated 20 mins after inhalation of 400 µg of salbutamol, to determine the presence of any reversibility. HRCT scanning (1 mm slices) was also performed and reported by an experienced thoracic radiologist, to identify patients with bronchial dilatation. The scans were reviewed some months later (without the initial report) with a senior respiratory physician, to obtain a consensus opinion on the presence of bronchiectasis, using the criteria first described by Naidich et al. 14 and recently reviewed by Hansell 15. Patients with tubular bronchiectasis were excluded from the final analysis, as previous work has suggested that, even when clinically indistinguishable, these patients have more bronchial inflammation 16.

Biochemical analysis
Myeloperoxidase
Myeloperoxidase (MPO) activity was measured by a chromogenic substrate assay relative to a standard preparation of lysed neutrophils, as described previously 17, and used as a marker of sputum neutrophil content and activation. The results are expressed as arbitrary units·mL^–1 of sputum.

Neutrophil elastase
Elastase activity was assessed spectrophotometrically using the synthetic substrate methoxysuccinyl-ala-ala-pro-val-paranitroanilide (MeOSAAPVpNa; Sigma-Aldrich Company Ltd, Poole, Dorset, UK). Twenty µL of standard or sample were added to the wells of a microtitre plate (Life Technologies Ltd, Paisley, UK), followed by MeOSAAPVpNa (0.3 nM) in phosphate buffer (0.2 M, pH 8.0). The reaction was allowed to continue for 1 h at 37°C and then stopped by the addition of 200 µL of 1 N acetic acid. The absorbence was read at 410 nm and the activity derived from the standard curve by interpolation. The inter-assay coefficient of variation was <1%, with a lower limit of detection of 0.8 nM, and sample results below this level were taken as zero for statistical purposes.

Chemoattractants
Both interleukin-8 (IL-8) and leukotriene B₄ (LTB₄) were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R and D Systems Europe Ltd, Abingdon, UK and Amersham International plc, Buckinghamshire, UK, respectively). The characteristics and recovery of these assays has been described previously 17.

Sputum sol and serum albumin
Albumin was measured by radial immunodiffusion using a commercially available kit (The Binding Site Ltd, Birmingham, UK). The inter-assay coefficient of variation was <5% (n=6). Sputum sol:serum ratios (expressed as a percentage) were calculated, providing an assessment of protein "leakage" from the blood into the lung 18.

C-reactive protein
Serum C-reactive protein (CRP) was measured by radial immunodiffusion using a commercially available kit (The Binding Site Ltd, Birmingham, UK) with an inter-assay coefficient of variation of 2.2%. Five µL of standard or sample was added to each well, and the plate was incubated for at least 72 h at room temperature. Precipitation ring diameters were measured using an eye piece graticule, and a regression curve was constructed of the square of the diameter of the precipitation ring versus concentration of the standards. The concentration of protein in the unknown samples was calculated by interpolation from this standard curve. The lower limit of detection for this assay is 2 mg·L^–1, and sample results below this level were taken as zero for statistical purposes.

Statistical analysis
All statistical analyses were performed using the SPSS statistical package (Version 8.0. Chicago, IL, USA). Age and FEV₁ are expressed as mean±sd, and the patient groups were compared using the unpaired t-test. The Chi-squared or Fischer's exact test were used to compare categorical data between groups, and changes in sputum bacteriology, colour and free elastase within groups. Inflammatory data are expressed as median (interquartile range), and displayed graphically as box and whisker plots. Changes compared to presentation with the exacerbation were analysed using the Wilcoxon signed-rank test for paired data, and differences between patient groups were compared with the Mann-Whitney U-test. Two-tailed tests were used to determine differences between groups when stable, and single-tailed tests were used to determine the differences between the groups at the start of exacerbation, and within groups as the exacerbation resolved. The level of statistical significance was taken as <0.05.

	Results

TOP Abstract Methods Results Discussion Acknowledgements References

 
Eighty-four patients presented with an acute exacerbation of their lung disease and provided an adequate sputum sample for analysis at day 1. Although the definition of an exacerbation was broad, 82 of the 84 patients fulfilled the "gold-standard" criteria for exacerbations first described by Anthonisen et al. 2. Thirty-five had all three major symptoms (increased dyspnoea, sputum purulence and sputum volume), 38 had two major symptoms and nine had one major and one minor symptom (increasing cough or fever). The remaining two patients had changes in sputum viscosity alone, with and without malaise. Since the study was designed to assess the biochemical nature of the episode, they were also included in the data set. HRCT scanning showed evidence of tubular bronchiectasis in 15 patients (who were otherwise clinically indistinguishable) and these were excluded from further analysis. The remaining 69 patients had a clear improvement in their presenting symptoms by the time they were re-studied in the clinically stable state.

Twenty-seven of the patients had mucoid sputum at presentation with the exacerbation (referred to as mucoid bronchitics) and 42 had purulent sputum (referred to as purulent bronchitics). By definition the mucoid bronchitics had colourless or white sputum at presentation (colour number <3), whereas those with a purulent exacerbation had a higher (median; interquartile range) sputum colour number (4.0; 4.0–5.0; p<0.001).

Patient characteristics
The characteristics of the patients are summarized in table 1. There were no differences in the proportions of current smokers or of those on inhaled steroids or oral theophyllines prior to the start of the study.

Sputum microbiology at presentation
At presentation nine of the mucoid samples (33%) grew an identifiable pathogen, but the bacterial load was >10⁷ colony forming units (cfu)·mL^–1 in only five (19% of the total). The organisms cultured from these nine patients included H. parainfluenzae 5, nontypeable H. influenzae 3 and N. meningitidis 1. Conversely, most of the purulent samples (90%) had a positive bacterial culture at presentation and in the majority (83%), the bacterial load was >10⁷ cfu·mL^–1 (p<0.001 compared with the mucoid group). The organisms included H. influenzae 21, S. pneumoniae 7, M. catarrhalis 6 and H. parainfluenzae 4.

Inflammatory markers at presentation
At presentation, the mucoid bronchitics had significantly lower MPO and elastase activity (elastase detectable in only five samples; 19%), IL-8, LTB₄ and protein leakage than the purulent bronchitics (table 2). Notably, elastase activity was detectable in 32 (76%) of the samples from the latter group of patients (p<0.0001).

Inflammatory markers in the stable state
The biochemical data for the mucoid bronchitics was unaltered in the stable state. However, there was a significant decrease in most parameters in the purulent bronchitics, with the exception of IL-8, which remained essentially unaltered (table 3). Importantly, there had also been a marked decrease in the number of elastase positive samples (p<0.0001), with activity remaining detectable in only 34%. Data for the two bronchitic groups in the stable state (day 56) were similar, with the exception of IL-8, which remained higher (2p<0.02) in the group that had presented with purulent sputum.

The time course of the changes in biochemical parameters is summarized for the purulent bronchitics in figures 1–3. A significant reduction in all measures was seen by the fifth day of therapy and except for IL-8 (which rose again after therapy), this was maintained in the stable clinical state. There were no differences in either the time course or the degree of change between the patients who had received 5 or 10 days of antibiotic therapy (data not shown).

View larger version (18K): [in this window] [in a new window]   Fig. 1.— Changes in a) myeloperoxidase (MPO) and b) neutrophil elastase (NE) following commencement of treatment for a purulent exacerbation of chronic obstructive pulmonary disease. The horizontal line is the median value, the box is the interquartile range and the whiskers indicate the range, excluding outlying and extreme values (i.e. points with values 1.5 box lengths from the upper or lower limits of the box). Although all patients were able to provide sufficient sputum for analysis at presentation, it was not possible to obtain adequate samples from every patient at each visit during the subsequent follow-up period (no sputum available or inadequate volume for ultracentrifugation). The number of samples obtained at days 1, 5, 10, 28 and 56 were n=41, n=36, n=34, n=25 and n=33 for fig. a, respectively; and n=42, n=36, n=33, n=24 and n=32 for fig. b, respectively. #: p<0.005, significant differences compared to day 1. - - - : the lower limit of detection of the elastase assay.

View larger version (22K): [in this window] [in a new window]   Fig. 2.— Changes in a) interleukin-8 (IL-8) and b) leukotriene B4 (LTB4) following commencement of treatment for a purulent exacerbation of chronic bronchitis. The horizontal line is the median value, the box is the interquartile range and the whiskers indicate the range, excluding outlying and extreme values (i.e. points with values 1.5 box lengths from the upper or lower limits of the box). The number of samples obtained at days 1, 5, 10, 28 and 56 were n=41, n=36, n=33, n=24 and n=33 for fig. a, respectively; and n=42, n=36, n=34, n=24 and n=33, for fig. b, respectively. *: p<0.05; **: p<0.01; #: p<0.005; significant differences compared to day 1.

View larger version (18K): [in this window] [in a new window]   Fig. 3.— Changes in albumin ratio following commencement of treatment for a purulent exacerbation of chronic bronchitis. The horizontal line is the median value, the box is the interquartile range and the whiskers indicate the range, excluding outlying and extreme values (i.e. points with values 1.5 box lengths from the upper or lower limits of the box). The number of samples obtained at days 1, 5, 10, 28 and 56 were n=42, n=34, n=31, n=22 and n=32, respectively. #: p<0.005.

View larger version (14K): [in this window] [in a new window]   Fig. 4.— C-reactive protein (CRP) in bronchitic patients at presentation (day 1, ) and in the stable clinical state (day 56, ). The horizontal line is the median value, the box is the interquartile range and the whiskers indicate the range, excluding outlying and extreme values (i.e. points with values 1.5 box lengths from the upper and lower limits of the box). The number of samples obtained at days 1 and 56 were n=26 and n=25 for mucoid bronchitis, respectively; and n=38 and n=34 for purulent bronchitis, respectively. - - - : the lower limit of detection of the assay. *: p<0.05; #: p<0.005, significance of changes within each group. ***: p<0.001, significance of the difference between the groups at presentation.

	Discussion

TOP Abstract Methods Results Discussion Acknowledgements References

There was a minor reduction in sputum MPO activity in the mucoid group as a whole as the episode resolved, but this had returned to the exacerbation level when the subjects were seen in the stable clinical state. This change was not related to steroid therapy or to a relapse in symptoms and the implications remain unknown. Protein leakage also decreased during the first 14 days in this group, but this was confined to the patients who received inhaled steroids. This change is consistent with an anti-inflammatory effect of steroids, and is similar to the effect seen following oral corticosteroid therapy in the stable clinical state 19. However, other work has shown a significant reduction in sputum chemotactic activity as well as an increase in elastase inhibitory capacity in response to inhaled corticosteroids in the stable state, but not an effect on sol:serum albumin 11. The present findings suggest that inhaled corticosteroids reduce leakage of serum proteins into the airway during mucoid exacerbations. Although the implications of this are uncertain, the result would be consistent with a clinical benefit of inhaled steroids on severity of exacerbations 12 and oral steroids on more severe exacerbations of COPD necessitating either hospital attendance 20 or hospital admission 21–22, if increased protein leakage were a feature of these episodes. Clearly, further studies are indicated to determine this possibility.

Purulent exacerbations were associated with significant bronchial and systemic inflammation at presentation, and with positive sputum cultures in 90% of cases. The biochemical resolution of these exacerbations was rapid with results after 5 days being similar to those seen in the stable clinical state. There was no apparent difference in either the speed or magnitude of resolution of inflammation (data not shown) between patients receiving 5 or 10 days of antibiotic. Whether these changes would have occurred without antibiotics is unknown since it was thought unethical to withhold antimicrobial therapy from patients with a change in sputum purulence at presentation.

In the stable clinical state, the reductions in neutrophil influx and activation (MPO and neutrophil elastase), bronchial and systemic inflammation (albumin ratio and CRP, respectively), and in the concentrations of LTB₄ were maintained. This was associated with a marked reduction in positive bacterial isolates, indicating that the purulent exacerbations were probably related to new bacterial infection. There were, however, no significant changes in IL-8, suggesting that LTB₄ plays a more important role in airway inflammation in the patients with relatively mild exacerbations, treated in the community.

Similar results were presented in a recent prospective study of outpatients with COPD, where there was no change in the concentration of IL-8 in induced sputum at presentation with an exacerbation 23. Although these exacerbations described by Bhowmik et al. 2 fulfilled Anthonisen's criteria, sputum purulence was not an inclusion criterion, which may explain why there were no changes in sputum neutrophils, and strict comparison with the presented data is not possible. However, acute, purulent, bacterial exacerbations requiring admission to hospital are associated with more intense inflammation and greater concentrations of chemoattractants (10-fold higher) than in the present study 24, with marked elevations in IL-8 and LTB₄. These results, together with those presented here, would support a hierarchical contribution of chemoattractants 25, with LTB₄ being the first to change at low levels of neutrophil influx (mild purulent exacerbations), and IL-8 becoming increasingly involved as neutrophil influx and activation becomes more intense (in more severe, purulent exacerbations).

The concentration of IL-8 in the stable state was higher in patients who had presented with purulent sputum. Airway levels of this cytokine are related to airflow obstruction 26, smoking status 27 and bacterial colonization 28, 29. The purulent bronchitics were more obstructed, on average, than the mucoid patients (although this just failed to achieve a conventional level of statistical significance). This could explain the difference in IL-8 between the two groups, since they were otherwise matched for bacterial colonization in the stable state and for smoking status. A final possibility is that these patients represent a group prone to frequent exacerbations, supporting the findings of Bhowmik et al. 23. Further studies are necessary to resolve this possibility.

In the present study, biochemical analyses have been performed on sputum samples from a large number of patients who were followed prospectively from the onset of an acute exacerbation of chronic bronchitis to its resolution. The presented data provide clear evidence of two types of exacerbation, which could be differentiated by sputum colour at presentation. Mucoid exacerbations appeared to be unrelated to bacterial infection and were not associated with neutrophilic inflammation. Purulent exacerbations were associated with significant bronchial and systemic inflammation and positive bacterial cultures, suggesting that they were related to bacterial infection; leukotriene B₄ appeared to be an important chemoattractant in these patients.

	Acknowledgements

TOP Abstract Methods Results Discussion Acknowledgements References

 
The authors acknowledge the central role of three respiratory research nurses, B. Leung, K. Verbeet and M. Henson, in patient recruitment and encouragement.

	References

TOP Abstract Methods Results Discussion Acknowledgements References

 

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77–S120.
2. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.
3. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846–850.[Abstract]
4. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies and bronchoalveolar lavage. Am J Respir Crit Care Med 1995;152:1926–1931.[Abstract]
5. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646–1652.[Abstract]
6. Stockley RA, Burnett D. Alpha1-antitrypsin and leukocyte elastase in infected and non-infected sputum. Am Rev Respir Dis 1979;120:1081–1086.[Web of Science][Medline] [Order article via Infotrieve]
7. Sachs APE, Koëter GH, Groenier KH, van der Waajj D, Schiphuis J, Meyboom-de-Jong B. Changes in symptoms, peak expiratory flow rate, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758–763.[Abstract/Free Full Text]
8. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635–642.[Abstract/Free Full Text]
9. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996;26:766–774.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
10. Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol 1995;48:719–724.[Abstract/Free Full Text]
11. Llewellyn-Jones CG, Harris TAJ, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616–621.[Abstract]
12. Paggiaro PL, Dahle R, Bakrani I, Frith L, Hollingworth K, Efthmiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773–780.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
13. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:1067–1083.[Web of Science][Medline] [Order article via Infotrieve]
14. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr 1982;6:437–444.[Web of Science][Medline] [Order article via Infotrieve]
15. Hansell DM. Bronchiectasis In: Webb WR, ed. Imaging in obstructive pulmonary diseasePhiladelphia, WB Saunders Company, 1998; pp. 107––128.
16. Gompertz S, O'Brien C, Bayley D, Leung B, Hill SL, Stockley RA. Comparison of stable state bronchial inflammation in chronic bronchitis and previously unsuspected bronchiectasis (BE). Eur Respir J 1999;14:Suppl. 30, 165S.
17. Stockley RA, Bayley D. Validation of assays for lung inflammatory markers. Eur Respir J 2000;15:778–781.[Abstract]
18. Stockley RA, Hill SL, Morrison HM, Starkie CM. Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis. Thorax 1984;39:408–413.[Abstract/Free Full Text]
19. Wiggins J, Elliot JA, Stevenson RD, Stockley RA. Effect of corticosteroids on sputum sol-phase protease inhibitors in chronic obstructive pulmonary disease. Thorax 1982;37:652–656.[Abstract/Free Full Text]
20. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407–412.[Abstract]
21. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456–460.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
22. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941–1947.[Abstract/Free Full Text]
23. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relationship of sputum inflammatory changes to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114–120.[Abstract/Free Full Text]
24. Crooks S, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B₄. Eur Respir J 2000;15:274–280.[Abstract]
25. Hill AT, Bayley DL, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160:893–898.[Abstract/Free Full Text]
26. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505–510.[Abstract/Free Full Text]
27. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and -1-antitrypsin deficiency. Eur Respir J 2000;15:886–890.[Abstract]
28. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubert A. Airway inflammation and bronchial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015–1022.[Abstract]
29. Hill AT, Campbell EJ, Hill SL, Crooks S, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288–295.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				A Di Stefano, G Caramori, I Gnemmi, M Contoli, L Bristot, A Capelli, F L M Ricciardolo, F Magno, S E. D'Anna, A Zanini, et al. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD Thorax, November 1, 2009; 64(11): 968 - 975. [Abstract] [Full Text] [PDF]

				A. Anzueto and M. Miravitlles Efficacy of tiotropium in the prevention of exacerbations of COPD Therapeutic Advances in Respiratory Disease, June 1, 2009; 3(3): 103 - 111. [Abstract] [PDF]

				S. Sethi and T. F. Murphy Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., November 27, 2008; 359(22): 2355 - 2365. [Full Text] [PDF]

				B M Roede, P Bresser, P J E Bindels, A Kok, M Prins, G t. Riet, R B Geskus, R M C Herings, and J M Prins Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study Thorax, November 1, 2008; 63(11): 968 - 973. [Abstract] [Full Text] [PDF]

				J. Holme, J. W. Tomlinson, R. A. Stockley, P. M. Stewart, N. Barlow, and A. L. Sullivan Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids Eur. Respir. J., October 1, 2008; 32(4): 1047 - 1052. [Abstract] [Full Text] [PDF]

				T. E. McManus, A-M. Marley, N. Baxter, S. N. Christie, J. S. Elborn, H. J. O'Neill, P. V. Coyle, and J. C. Kidney High levels of Epstein-Barr virus in COPD Eur. Respir. J., June 1, 2008; 31(6): 1221 - 1226. [Abstract] [Full Text] [PDF]

				D. C. Newcomb, U. S. Sajjan, D. R. Nagarkar, Q. Wang, S. Nanua, Y. Zhou, C. L. McHenry, K. T. Hennrick, W. C. Tsai, J. K. Bentley, et al. Human Rhinovirus 1B Exposure Induces Phosphatidylinositol 3-Kinase-dependent Airway Inflammation in Mice Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1111 - 1121. [Abstract] [Full Text] [PDF]

				V. Kim, T. J. Rogers, and G. J. Criner New Concepts in the Pathobiology of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 478 - 485. [Abstract] [Full Text] [PDF]

				D. L. Bayley, H. Abusriwil, A. Ahmad, and R. A. Stockley Validation of assays for inflammatory mediators in exhaled breath condensate Eur. Respir. J., May 1, 2008; 31(5): 943 - 948. [Abstract] [Full Text] [PDF]

				S. Sethi and T. F. Murphy Bacterial Load and Exacerbations of COPD Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1049 - 1049. [Full Text] [PDF]

				H. Abusriwil and R. A. Stockley Bacterial Load and Exacerbations of COPD Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1048 - 1049. [Full Text] [PDF]

				W. MacNee Update in Chronic Obstructive Pulmonary Disease 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829. [Full Text] [PDF]

				T. F. Murphy, A. L. Brauer, K. Eschberger, P. Lobbins, L. Grove, X. Cai, and S. Sethi Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 853 - 860. [Abstract] [Full Text] [PDF]

				S. Sethi, C. Wrona, K. Eschberger, P. Lobbins, X. Cai, and T. F. Murphy Inflammatory Profile of New Bacterial Strain Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 491 - 497. [Abstract] [Full Text] [PDF]

				S. W. Chung, A. Toriba, H. Y. Chung, B. P. Yu, T. Kameda, N. Tang, R. Kizu, and K. Hayakawa Activation of 5-Lipoxygenase and NF-{kappa}B in the Action of Acenaphthenequinone by Modulation of Oxidative Stress Toxicol. Sci., January 1, 2008; 101(1): 152 - 158. [Abstract] [Full Text] [PDF]

				S. Siddiqui, F. Hollins, S. Saha, and C. E. Brightling Inflammatory cell microlocalisation and airway dysfunction: cause and effect? Eur. Respir. J., December 1, 2007; 30(6): 1043 - 1056. [Abstract] [Full Text] [PDF]

				H. Abusriwil and R. A. Stockley The Interaction of Host and Pathogen Factors in Chronic Obstructive Pulmonary Disease Exacerbations and Their Role in Tissue Damage Proceedings of the ATS, December 1, 2007; 4(8): 611 - 617. [Abstract] [Full Text] [PDF]

				A. Sykes, P. Mallia, and S. L. Johnston Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 642 - 646. [Abstract] [Full Text] [PDF]

				M. Miravitlles Review: Do we need new antibiotics for treating exacerbations of COPD? Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 61 - 76. [Abstract] [PDF]

				A. Anzueto, S. Sethi, and F. J. Martinez Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 554 - 564. [Abstract] [Full Text] [PDF]

				D. C. Newcomb, U. S. Sajjan, D. R. Nagarkar, A. M. Goldsmith, J. K. Bentley, and M. B. Hershenson Cooperative effects of rhinovirus and TNF-{alpha} on airway epithelial cell chemokine expression Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L1021 - L1028. [Abstract] [Full Text] [PDF]

				S. Sethi, R. Sethi, K. Eschberger, P. Lobbins, X. Cai, B. J. B. Grant, and T. F. Murphy Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 356 - 361. [Abstract] [Full Text] [PDF]

				T. Yoshida and R. M. Tuder Pathobiology of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Physiol Rev, July 1, 2007; 87(3): 1047 - 1082. [Abstract] [Full Text] [PDF]

				B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]

				C. G. Cote, L. J. Dordelly, and B. R. Celli Impact of COPD Exacerbations on Patient-Centered Outcomes Chest, March 1, 2007; 131(3): 696 - 704. [Abstract] [Full Text] [PDF]

				W. R. Perera, J. R. Hurst, T. M. A. Wilkinson, R. J. Sapsford, H. Mullerova, G. C. Donaldson, and J. A. Wedzicha Inflammatory changes, recovery and recurrence at COPD exacerbation Eur. Respir. J., March 1, 2007; 29(3): 527 - 534. [Abstract] [Full Text] [PDF]

				J. K. Bentley, D. C. Newcomb, A. M. Goldsmith, Y. Jia, U. S. Sajjan, and M. B. Hershenson Rhinovirus Activates Interleukin-8 Expression via a Src/p110{beta} Phosphatidylinositol 3-Kinase/Akt Pathway in Human Airway Epithelial Cells J. Virol., February 1, 2007; 81(3): 1186 - 1194. [Abstract] [Full Text] [PDF]

				D. Stolz, M. Christ-Crain, R. Bingisser, J. Leuppi, D. Miedinger, C. Muller, P. Huber, B. Muller, and M. Tamm Antibiotic Treatment of Exacerbations of COPD: A Randomized, Controlled Trial Comparing Procalcitonin-Guidance With Standard Therapy Chest, January 1, 2007; 131(1): 9 - 19. [Abstract] [Full Text] [PDF]

				V. M. Pinto-Plata, G. Livnat, M. Girish, H. Cabral, P. Masdin, P. Linacre, R. Dew, L. Kenney, and B. R. Celli Systemic Cytokines, Clinical and Physiological Changes in Patients Hospitalized for Exacerbation of COPD Chest, January 1, 2007; 131(1): 37 - 43. [Abstract] [Full Text] [PDF]

				A. Roghanian, E. M. Drost, W. MacNee, S. E. M. Howie, and J.-M. Sallenave Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1189 - 1198. [Abstract] [Full Text] [PDF]

				J. R. Hurst, G. C. Donaldson, W. R. Perera, T. M. A. Wilkinson, J. A. Bilello, G. W. Hagan, R. S. Vessey, and J. A. Wedzicha Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 867 - 874. [Abstract] [Full Text] [PDF]

				P. Mallia and S. L. Johnston How viral infections cause exacerbation of airway diseases. Chest, October 1, 2006; 130(4): 1203 - 1210. [Abstract] [Full Text] [PDF]

				U. S. Sajjan, Y. Jia, D. C. Newcomb, J. K. Bentley, N. W. Lukacs, J. J. LiPuma, and M. B. Hershenson H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression FASEB J, October 1, 2006; 20(12): 2121 - 2123. [Abstract] [Full Text] [PDF]

				A. Papi, C. M. Bellettato, F. Braccioni, M. Romagnoli, P. Casolari, G. Caramori, L. M. Fabbri, and S. L. Johnston Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1114 - 1121. [Abstract] [Full Text] [PDF]

				A. Papi, F. Luppi, F. Franco, and L. M. Fabbri Pathophysiology of Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2006; 3(3): 245 - 251. [Abstract] [Full Text] [PDF]

				J. Vestbo Clinical Assessment, Staging, and Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, May 1, 2006; 3(3): 252 - 256. [Abstract] [Full Text] [PDF]

				E Sapey and R A Stockley COPD exacerbations {middle dot} 2: Aetiology. Thorax, March 1, 2006; 61(3): 250 - 258. [Abstract] [Full Text] [PDF]

				J. R. Hurst, W. R. Perera, T. M. A. Wilkinson, G. C. Donaldson, and J. A. Wedzicha Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 71 - 78. [Abstract] [Full Text] [PDF]

				D. C. Newcomb, U. Sajjan, S. Nanua, Y. Jia, A. M. Goldsmith, J. K. Bentley, and M. B. Hershenson Phosphatidylinositol 3-Kinase Is Required for Rhinovirus-induced Airway Epithelial Cell Interleukin-8 Expression J. Biol. Chem., November 4, 2005; 280(44): 36952 - 36961. [Abstract] [Full Text] [PDF]

				P. Mallia and S. L. Johnston Mechanisms and Experimental Models of Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, November 1, 2005; 2(4): 361 - 366. [Abstract] [Full Text] [PDF]

				P Montuschi, F Macagno, P Parente, S Valente, L Lauriola, G Ciappi, S A Kharitonov, P J Barnes, and G Ciabattoni Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD Thorax, October 1, 2005; 60(10): 827 - 833. [Abstract] [Full Text] [PDF]

				T. G. Brock, Y.-J. Lee, E. Maydanski, T. L. Marburger, M. Luo, R. Paine III, and M. Peters-Golden Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L224 - L232. [Abstract] [Full Text] [PDF]

				P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]

				M. Tsoumakidou, N. Tzanakis, G. Chrysofakis, and N. M. Siafakas Nitrosative Stress, Heme Oxygenase-1 Expression and Airway Inflammation During Severe Exacerbations of COPD Chest, June 1, 2005; 127(6): 1911 - 1918. [Abstract] [Full Text] [PDF]

				K. Kostikas, M. Gaga, G. Papatheodorou, T. Karamanis, D. Orphanidou, and S. Loukides Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma Chest, May 1, 2005; 127(5): 1553 - 1559. [Abstract] [Full Text] [PDF]

				A. Rosell, E. Monso, N. Soler, F. Torres, J. Angrill, G. Riise, R. Zalacain, J. Morera, and A. Torres Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease Arch Intern Med, April 25, 2005; 165(8): 891 - 897. [Abstract] [Full Text] [PDF]

				K. Fujimoto, M. Yasuo, K. Urushibata, M. Hanaoka, T. Koizumi, and K. Kubo Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease Eur. Respir. J., April 1, 2005; 25(4): 640 - 646. [Abstract] [Full Text] [PDF]

				P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF]

				R. A. Pauwels Similarities and Differences in Asthma and Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, April 1, 2004; 1(2): 73 - 76. [Abstract] [Full Text] [PDF]

				S. Sethi Bacteria in Exacerbations of Chronic Obstructive Pulmonary Disease: Phenomenon or Epiphenomenon? Proceedings of the ATS, April 1, 2004; 1(2): 109 - 114. [Abstract] [Full Text] [PDF]

				P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellularmechanisms Eur. Respir. J., October 1, 2003; 22(4): 672 - 688. [Abstract] [Full Text] [PDF]

				A. Ahmad, D. L. Bayley, S. He, and R. A. Stockley Myeloid Related Protein-8/14 Stimulates Interleukin-8 Production in Airway Epithelial Cells Am. J. Respir. Cell Mol. Biol., October 1, 2003; 29(4): 523 - 530. [Abstract] [Full Text] [PDF]

				A Agusti, W MacNee, K Donaldson, and M Cosio Hypothesis: Does COPD have an autoimmune component? Thorax, October 1, 2003; 58(10): 832 - 834. [Full Text]

				A J White, S Gompertz, D L Bayley, S L Hill, C O'Brien, I Unsal, and R A Stockley Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis Thorax, August 1, 2003; 58(8): 680 - 685. [Abstract] [Full Text] [PDF]

				R.O. Crapo, R.L. Jensen, and F.E. Hargreave Airway inflammation in COPD: physiological outcome measures and induced sputum Eur. Respir. J., June 1, 2003; 21(41_suppl): 19S - 28s. [Abstract] [Full Text] [PDF]

				W A Biernacki, S A Kharitonov, and P J Barnes Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD Thorax, April 1, 2003; 58(4): 294 - 298. [Abstract] [Full Text] [PDF]

				A J White, S Gompertz, and R A Stockley Chronic obstructive pulmonary disease * 6: The aetiology of exacerbations of chronic obstructive pulmonary disease Thorax, January 1, 2003; 58(1): 73 - 80. [Abstract] [Full Text] [PDF]

				S. Gompertz and R. A. Stockley A Randomized, Placebo-Controlled Trial of a Leukotriene Synthesis Inhibitor in Patients With COPD* Chest, July 1, 2002; 122(1): 289 - 294. [Abstract] [Full Text] [PDF]

				M. Miravitlles Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s. [Abstract] [Full Text] [PDF]

				C. Sohy, C. Pilette, M.S. Niederman, and Y. Sibille Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed? Eur. Respir. J., May 1, 2002; 19(5): 966 - 975. [Abstract] [Full Text] [PDF]

				R. A. Stockley Neutrophils and the Pathogenesis of COPD* Chest, May 1, 2002; 121 (2009): 151S - 155S. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (86) Citing Articles via Google Scholar Google Scholar Articles by Gompertz, S. Articles by Stockley, R.A. Search for Related Content PubMed PubMed Citation Articles by Gompertz, S. Articles by Stockley, R.A.